



Ambrosia Biosciences

June 2026

Ambrosia is developing orally available small-molecule therapies targeting GLP-1 and related receptors for safe, effective, affordable metabolic treatment, enabling combination and personalized patient care.

Why Oral Small Molecules?



Peptides - Inherent Delivery and Scaling Challenges:

- **Poor oral bioavailability** typically necessitates injection - limiting patient adoption and adherence
- Oral versions require large doses and offer **inconsistent performance** in real world
- **Manufacturing** is complex and resource-intensive
- Delivery devices **increase cost and waste**
- **Cold-chain requirement** hampers distribution, particularly at global scale



Small Molecules - Patient-Friendly Delivery with Scalable Economics:

- **Oral dosing preferred** by patients and supports flexible, personalized titration
- **Scalable, lower COGs** manufacturing
- **Stable** at room temperature
- **No delivery device**; less waste

Oral Small Molecule Discovery Pipeline

GLP-1R Agonist
QD Dosing

DC/IND-enabling studies

Developing a differentiated GLP-1 molecule demonstrating best-in-class potential, based on a novel structural approach and emphasis on lower effective human dosing, superior 24-hour target coverage, and improved combinability.

GLP-1R Agonist
QW Dosing

Discovery

Extended half-life to enable once weekly dosing, while maintaining performance differentiation attributes of daily GLP-1R agonist.

GIPR Antagonist

Discovery


Combination dosing with GLP1-RA to amplify efficacy while maintaining tolerability, as well as potential for maintenance dosing.

Amylin Agonist

Discovery

Once daily monotherapy or in combination with synergistic therapies, such as GLP-1RA.

Ambrosia Snapshot

Proven drug discovery team from 

Investors:

BVF Partners, Boulder Ventures, Blue Owl Healthcare Opp, Deep Track, Redmile, Janus, Samsara and Merck

Team:

- Founding scientific team with a proven track record in all stages of structure-based drug discovery
- Contributed to *30 IND filings on 25 NMEs and 7 FDA approvals*

Boulder, CO Facilities (24,000 sq. ft.):

- **Fully integrated chemistry & biology operations** enabling rapid iteration
- **NMR, structural biology, & AI-enabled molecular design** supporting GPCR discovery
- **BSL-2 & in vitro ADME labs** for rapid preclinical screening

Ambrosia Team

Experienced drug developers and company builders



Nick Traggis
Founder and CEO



Patrice Lee, PhD
President, R&D



Erik Hicken, PhD
Head of Chemistry



Andrea Flynn, PhD
Chief Business Officer




Faraz Naqvi, MD
Founder, Medical Director



Ben Carver
Founder, General Counsel



Kenny Edwards
Vice President, Finance



Matthew Martinson
Vice President, Operations



Ambrosia Timeline



\$25MM Series A Financing

- Led by Merck, BVF Partners and Boulder Ventures
- Recruit founding science team from Array/Pfizer

Nominated Development Candidate: GLP-1 RA

- Initiate IND enabling studies

\$100M Series B Financing

- Led by Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital
- Advance small molecule pipeline into clinic

2024

2025

2026

Began Laboratory Operations in Boulder, CO

- Begin to interrogate small molecule candidates

2026: Continue to Advance Oral Small Molecule Pipeline

- GLP-1RA
- GIPR
- Amylin
- Undisclosed



Contact:
info@ambrosia.health